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Background: Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory
condition. Approximately 15–20% of patients develop symptoms before their 18th birthday
and are diagnosed with juvenile-onset SLE (JSLE). Gender distribution, clinical presentation,
disease courses and outcomes vary significantly between JSLE patients and individuals with
adult-onset SLE. This study aimed to identify age-specific clinical and/or serological patterns
in JSLE patients enrolled to the UK JSLE Cohort Study. Methods: Patient records were
accessed and grouped based on age at disease-onset: pre-pubertal (7 years), peri-pubertal
(8–13 years) and adolescent (14–18 years). The presence of American College of
Rheumatology (ACR) classification criteria, laboratory results, disease activity [British Isles
Lupus Assessment Group (BILAG) and Systemic Lupus Erythematosus Disease Activity
Index 2000 (SLEDAI-2K) scores] and damage [Systemic Lupus International Collaborating
Clinics (SLICC) damage index] were evaluated at diagnosis and last follow up. Results: A
total of 418 JSLE patients were included in this study: 43 (10.3%) with pre-pubertal disease
onset; 240 (57.4%) with peri-pubertal onset and 135 (32.3%) were diagnosed during adoles-
cence. At diagnosis, adolescent JSLE patients presented with a higher number of ACR criteria
when compared with pre-pubertal and peri-pubertal patients [pBILAG2004 scores: 9(4–20] vs.
7(3–13] vs. 7(3–14], respectively, p¼ 0.015] with increased activity in the following BILAG
domains: mucocutaneous (p¼ 0.025), musculoskeletal (p¼ 0.029), renal (p¼ 0.027) and car-
diorespiratory (p¼ 0.001). Furthermore, adolescent JSLE patients were more frequently
ANA-positive (p¼ 0.034) and exhibited higher anti-dsDNA titres (p¼ 0.001). Pre-pubertal
individuals less frequently presented with leukopenia (p¼ 0.002), thrombocytopenia
(p¼ 0.004) or low complement (p¼ 0.002) when compared with other age groups. No differ-
ences were identified in disease activity (pBILAG2004 score), damage (SLICC damage index)
and the number of ACR criteria fulfilled at last follow up. Conclusions: Disease presentations
and laboratory findings vary significantly between age groups within a national cohort of
JSLE patients. Patients diagnosed during adolescence exhibit greater disease activity and
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‘‘classic’’ autoantibody, immune cell and complement patterns when compared with younger
patients. This supports the hypothesis that pathomechanisms may vary between patient age
groups. Lupus (2020) 29, 474–481.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic
autoimmune/inflammatory condition that can
affect any organ system and result in significant
damage and organ failure.1,2 Clinical characteris-
tics, underlying pathomechanisms, disease progres-
sion and outcomes vary between individuals, age
groups and races. Approximately 15–20% of SLE
patients develop the disease before their 18th birth-
day and are therefore diagnosed with juvenile-onset
SLE (JSLE).1,2 Juvenile-onset disease is associated
with more severe organ involvement (including
renal and CNS disease), increased disease activity,
presence of greater damage at the time of diagnosis,
and higher steroid burden, contributing to the
increased morbidity and mortality when compared
with adult-onset SLE3–5. Even within the JSLE
population, very early disease onset (before the
5th birthday) may be associated with atypical pres-
entations (including fewer autoantibodies), more
severe disease course and poor prognosis.1,6–8
However, assumptions on variable disease presen-
tation and progression within different JSLE age
subgroups are generally based on case reports,
case series or relatively small cohorts,7,8 and cur-
rently lack scientific evidence from longitudinal
national or international studies.
Preliminary datasets suggest that clinical differ-
ences may reflect variable pathomechanisms and
that patients with JSLE may have increased genetic
burden when compared with individuals with adult-
onset disease, contributing to early disease onset
and more severe presentations.1,9 Very early disease
onset, atypical disease presentation and severe
manifestations may be the result of (very rare)
disease-causing mutations in single genes or the
combination of multiple genomic variants that indi-
vidually increase an individual’s risk for the devel-
opment of SLE.1,9–11 To date, evidence still remains
weak and it is largely unclear whether distinct clin-
ical and laboratory differences exist between age
groups within the paediatric population.1,12,13
This study aimed to assess if there are differential
clinical and laboratory characteristics in patients
presenting with JSLE at different ages, subdividing
patients into three groups: pre-pubertal (7 years),
peri-pubertal (8–13 years) or adolescence (14–18
years). To achieve this, prospectively collected
data from a national cohort of JSLE patients (the
UK JSLE Cohort Study) was interrogated.
Methods
Patients
Participants of the UK JSLE Cohort Study,14 fol-
lowed between 2006 and 2018, aged 16 years at
the time of diagnosis and with at least four
American College of Rheumatology (ACR) classi-
fication criteria for SLE,15 were included in this
study. Participants were excluded from the study
if they did not have a diagnosis date recorded, as
this precluded them from being categorized on the
basis on their age at disease-onset [pre-pubertal
(7 years), peri-pubertal (8–13 years) or adolescent
(14–18 years)]. Patient/family-reported ethnicity
information was collected using UK National
Census categories.12 Data of patients of mixed
race were grouped with those of the associated
ethnic minority group (e.g. Asian if mixed Asian
and Caucasian race). Of note, distribution among
ethnicities did not vary between age groups (see
Results, supplemental Tables S1 and S2).
Data collected
The following clinical and laboratory data were
collected: (a) total ACR score with its individual
domains;15 (b) antinuclear antibody (ANA) positiv-
ity and titre; (c) Systemic Lupus International
Collaborating Clinics standardised damage
index (SLICC-SDI) score;16 (d) Systemic Lupus
Erythematosus Disease Activity Index 2000
(SLEDAI-2K) score;17 (e) paediatric British Isles
Lupus Assessment Grade 2004 numerical scores
(pBILAG2004) with individual organ/system
domains (alphabetical score A–E)18; (f) key labora-
tory findings, including haemoglobin levels, white
cell count and differentiation, platelets, erythrocyte
sedimentation rate (ESR), complement levels (C3,
C4) and anti-double-stranded DNA (dsDNA)
titres.
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The SLICC-SDI tool records permanent damage
that occurs as a result of SLE activity, and is com-
posed of 41 different components.16 The SLEDAI-
score is a widely used measure of lupus disease
activity, providing numerical scores based on a
count of laboratory and clinical symptoms.17 The
pBILAG2004 score is a composite disease activity
measure focusing on nine organ/system domains
(constitutional, mucocutaneous, neurological, mus-
culoskeletal, cardiovascular/respiratory, renal,
gastrointestinal, ophthalmic and haematological).
Each organ domain is graded A–E and defined as
follows; pBILAG2004 grade A/B: severe and mod-
erate disease respectively, grade C patients: mild/
improving renal disease, grade D: inactive disease
but previous system involvement, grade E: system
has never been involved.19,20 For each organ/
system domain, an alphabetical (A–E grade) is
determined, equating to a numerical value for
each organ/system domain. These can be combined
to give the total numerical pBILAG2004 score.18
Within these analyses, presence of pBILAG2004
domains A and B was taken to signify active
organ/system involvement, in keeping with previ-
ous studies.18 All data items (a–e listed above)
were collected at the time of initial diagnosis. At
the patients’ last follow-up visit, data from items
a and d were collected. Furthermore, data from
item e were collected from patients as their cumu-
lative maximum disease activity level (for each
individual organ/system domain) throughout the
disease course.
Statistical analysis
Laboratory findings, total number of ACR criteria,
SLICC, SLEDAI-2K and pBILAG2004 scores
were compared between groups using Kruskal-
Wallis tests. Median values and interquartile
ranges (IQRs) are displayed within tables.
Categorical pBILAG2004 domain data is presented
as a percentage of patients with active organ/system
involvement for each age group along with 95%
confidence intervals. Individual domains of the
pBILAG2004 score were compared between
groups using Chi-square and Fisher’s exact tests.
Analyses were completed using SPSS software, ver-
sion 25 (IBM SPSS).
Power analysis revealed that the three patient
groups should all have approximately 700 patients
each to reach sufficient statistical power. Limited by
the rarity of JSLE and resulting number of patients
included in the national UK JSLE cohort study
since 2006, these numbers are extremely difficult
to obtain in national, or even international,
cohorts. Thus, p values of statistical tests should
be interpreted with caution, based upon the limited
statistical power of this study.
Ethics
Written patient assent/consent and/or, where
appropriate, parental consent was obtained for
inclusion of patients within the UK JSLE Cohort
Study. The UK JSLE Cohort Study has full ethical
approval from the National Research Ethics
Service North West, Liverpool East (REC reference
06/Q1502/77). This research was carried out in
accordance with the decleration of Helsinki.
Results
Demographics
A total of 418 eligible patients enrolled in the UK
JSLE Cohort Study were included in this study; five
JSLE patients were excluded due to unknown age
at diagnosis. The mean age at diagnosis was 12.1
years (range: 0.17–17.91), with 43/418 (10.3%) par-
ticipants presenting in the pre-pubertal period, 240/
418 (57.4%) were peri-pubertal, and 135/418
(32.3%) were in the adolescent age group. The
overall female:male ratio was 5.4:1 and increased
with age (pre-pubertal¼ 3.3:1; peri-pubertal¼
5.24:1; adolescent¼ 7.25:1). No statistically signifi-
cant differences were demonstrated between groups
in relation to ethnicity (p> 0.05) (Supplemental
Tables S1 and S2).
Clinical features
At diagnosis, adolescent JSLE patients exhibited
higher median ACR scores when compared with
younger JSLE patients [pre-pubertal: median
4(IQR 4–5) vs. peri-pubertal: 4(4–5) vs. adolescent:
5(4–6), p¼ 0.004]. Similarly, pBILAG2004 disease
activity scores were higher in newly diagnosed ado-
lescent JSLE patients [pBILAG2004: 9(4–20)]
when compared with younger JSLE patients [pre-
pubertal: 7(3–13); peri-pubertal: 7(3–14), p¼ 0.015]
(Table 1). First SLEDAI-2K scores were also
higher in the adolescent population [pre-pubertal:
8(4–14); peri-pubertal 8(4–14); adolescent 12(6–18),
p¼ 0.001] (Table 1). Furthermore, adolescents with
a new diagnosis of JSLE exhibited more activity in
the following pBILAG domains when compared
with new peri-pubertal and pre-pubertal JSLE
patients: mucocutaneous (p¼ 0.025), musculoskel-
etal (p¼ 0.029), cardiorespiratory (p¼ 0.001) and
renal (p¼ 0.027) (Table 1).
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At the time of last follow up, differences were not
apparent between age groups in terms of total ACR
scores [median of 5(IQR 4–7) in all groups], disease
activity shown through SLEDAI-2K [pre-pubertal:
8(5–8); peri-pubertal: 8(6–8); adolescent 7(5–8),
p¼ 0.689] or antinuclear antibodies (ANA) posi-
tivity. Over the disease course active organ/system
involvement (as defined by the pBILAG2004 score)
also did not differ significantly between age groups
(Table 2). There was little variance in SLICC-
SDI defined damage at diagnosis (p¼ 0.410) or
last follow-up (p¼ 0.284) between age groups
(Tables 1 and 2).
Laboratory features
Laboratory findings varied between JSLE patients
from different age groups at diagnosis (Table 3).
White blood cell and platelet counts reduced with
growing age across the JSLE cohort; with pre-pub-
ertal patients exhibiting median white cell counts of
6.7 109/L [4.69–9.53] vs. 6.09 109/L [4.16–8.67]
in peri-pubertal vs. 4.69 109/L [3.7–6.54] in the
adolescent age group (p¼ 0.002). Median platelet
counts were within the normal range, but followed
a similar pattern to the white cell count, with
293 109/L [212–426] in the pre-pubertal group
vs. 271 109/L [191–388] in the peri-pubertal vs.
242 109/L [168–298] in the adolescent group
(p¼ 0.004). Median levels of haemoglobin
(p¼ 0.404) and ESR (p¼ 0.2) did not differ between
age groups (Table 3).
Serum complement is a measure of disease activ-
ity in SLE as it indicates activation and consump-
tion of complement components,21 Median
complement levels differed significantly between
age groups, with higher complement levels in
younger patients [C3: 0.95 g/L (0.73–1.11) in pre-
pubertal patients vs. 0.81 g/L (0.50–1.22) in peri-
pubertal vs. 0.69 g/L (0.28–0.98) in adolescent
patients (p¼ 0.002); C4: 0.13 g/L (0.08–0.28) in
pre-pubertal patients vs. 0.11 g/L (0.06–0.19) peri-
pubertal patients vs. 0.08 g/L (0.04–0.14) in adoles-
cent patients (p¼ 0.002)] (Table 3).
In the UK JSLE cohort, patients with disease-
onset during adolescence were more frequently
Table 1 Clinical features of JSLE subgroups at diagnosis
Item
Pre-pubertal disease-onset
(n¼ 43)
Peri-pubertal disease-onset
(n¼ 240) Adolescence (n¼ 135) p value
Female:male ratio 3.3:1 5.24:1 7.25:1 0.347
Total ACR score 4 [4–5] 4 [4–5] 5 [4–6] 0.004
SLICC-SDI 0 [0] 0 [0] 0 [0] 0.410
SLEDAI-2K 8 [4–14] 8 [4–14] 12 [6–18] 0.001
Total numerical pBILAG2004 score 7 [3–13] 7 [3–14] 9 [4–20] 0.015
Active organ/system involvement at diagnosis (pBILAG2004 defined)
 Constitutional 13 (30.2%)
[16.5%, 43.9%]
67 (27.9%)
[22.2%, 33.6%]
51 (37.8%)
[29.6%, 46.0%]
0.140
 Mucocutaneous 19 (44.2%)
[29.5%, 59.0%]
78 (32.5%)
(26.6%, 38.4%]
62 (45.9%)
[37.5%, 54.3%]
0.025
 Neuropsychiatric 6 (40.0%)
[25.4%, 54.6%]
20 (8.3%)
[4.8%, 11.8%]
14 (10.4%)
[5.3%, 15.3%]
0.477
 Musculoskeletal 7 (16.3%)
[5.3%, 27.3%]
66 (27.5%)
[21.9%, 33.1%]
49 (36.3%)
[28.2%, 44.4%]
0.029
 Cardiorespiratory 4 (9.3%)
[0.6%, 18%]
18 (7.5%)
[4.2%, 10.8%]
27 (20%)
[13.3%, 26.7%]
0.001
 Gastrointestinal 2 (4.7%)
[0%, 11%]
15 (6.3%)
[3.2%, 9.4%]
4 ((3.0%)
[0.1%, 5.9%]
0.442
 Ophthalmic 1 (2.3%)
[0%, 6.8%]
2 (0.8%)
[0%, 1.9%]
1 (0.7%)
[0%, 2.1%]
0.548
 Renal 9 (20.9%)
[8.7%, 33.1%]
73 (30.4%)
[24.6%, 36.2%]
55 (40.7%)
[32.4%, 49.0%]
0.027
 Haematological 11 (25.6%)
[12.6%, 38.6%]
58 (24.1%)
[18.7%, 29.5%]
37 (27.4%)
[19.9%, 34.9%]
0.786
Total ACR, SLICC-SDI, SLEDAI-2K, pBILAG2004 scores, and key laboratorial findings are reported as median values and interquartile ranges
[in square brackets]. For individual pBILAG2004 organs/systems involved, the total number of patients with active involvement (defined as
pBILAG2004 domain score of A or B within a given organ domain/system) is provided along with the percentage (in curved brackets) and
95% confidence intervals for the percentage [in square brackets].
ACR, American College of Rheumatology; BILAG, British Isles Lupus Assessment Group; JLSE, juvenile onset systemic lupus erythematous;
SLICC-SDI, Systemic Lupus International Collaborating Clinics-standardised damage index; SLEDAI-2K, Systemic Lupus Erythematosus
Disease Activity Index 2000.
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ANA-positive 131/135 (97.0%) at diagnosis, when
compared with the other age groups; 37/43 (86.0%)
with pre-pubertal onset, and 223/240 (92.9%) in peri-
pubertal onset (p¼ 0.034). Anti-dsDNA antibody
titres were higher in older patients than younger
patients; pre-pubertal onset 15 IU/L (0.25–89) vs.
67 IU/L (19–200) in peri-pubertal group vs. 111 IU/L
(15–300) in adolescents (p¼ 0.001) (Table 3).
Table 2 Clinical features of the different age groups over time
Items on last follow up
Pre-pubertal disease-onset
(n¼ 43)
Peri-pubertal disease-onset
(n¼ 240)
Adolescence
(n¼ 135) p value
Length of follow up in years 6 [3–9] 4 [2–6] 2 [1–4] <0.001
Total ACR score 5 [4–7] 5 [4–7] 5 [4–7] 0.686
SLICC-SDI score 0 [0–1] 0 [0–1] 0 [0–1] 0.284
SLEDAI-2K 8 [5–8] 8 [6–8] 7 [5–8] 0.689
ANA positivity 42 (97.7%)
[93.2%, 102.2%]
230 (95.8%)
[93.3%, 98.3%]
132 (97.8%)
[95.3%, 100.0%]
0.559
pBILAG2004 defined organ/system domain involvement throughout the disease course
Constitutional 18 (41.9%)
[27.2%, 56.6%]
98 (40.8%)
[34.1%, 46.5%]
56 (41.5%)
[33.2%, 49.8%]
0.988
Mucocutaneous 33 (76.7%)
[64.1%, 89.3%]
157 (65.4%)
[59.4%, 71.4%]
90 (66.7%)
[58.7%, 74.7%]
0.346
Neuropsychiatric 11 (25.6%)
[12.6%, 38.6%]
57 (27.9%)
[22.2%, 33.6%]
28 (20.7%)
[13.9%, 27.5%]
0.731
Musculoskeletal 18 (41.9%)
[16.5%, 43.9%]
121 (50.4%)
[44.1%, 56.7%]
73 (54.1%)
[45.7%, 62.5%]
0.374
Cardiorespiratory 13 (30.2%)
[16.5%, 43.9%]
46 (19.2%)
[14.2%, 24.2%]
35 (25.9%)
[18.5%, 33.3%]
0.141
Gastrointestinal 8 (18.6%)
[7.0%, 30.2%]
28 (11.7%)
[7.6%, 15.8%]
10 (7.4%)
[3.0%, 11.8%]
0.107
Ophthalmic 3 (7.0%)
[0%, 14.6%]
12 (5.0%)
[2.2%, 7.8%]
4 (3.0%)
[0.1%, 5.9%]
0.467
Renal 28 (65.1%)
[50.9%, 79.3%]
153 (63.8%)
[57.7%, 69.9%]
94 (69.6%)
[61.8%, 77.4%]
0.513
Haematological 26 (60.5%)
[45.9%, 75.1%]
114 (47.5%)
[41.2%, 53.8%]
55 (40.7%)
[32.4%, 49.0%]
0.072
Total ACR, SLICC-SDI, SLEDAI-2K, pBILAG2004 scores are reported as median values and interquartile ranges. For individual pBILAG2004
domains, the total number of patients with activity involvement (defined as a pBILAG2004 domain score of A or B in a given organ domain/
system) are provided along with percentage (in curved brackets), and 95% confidence intervals for the percentage [square brackets]. SLICC-SDI
and ACR scores are provided from the last follow-up visit.
ACR, American College of Rheumatology; ANA, antinuclear antibodies; BILAG, British Isles Lupus Assessment Group; SLICC-SDI, Systemic
Lupus International Collaborating Clinics-standardised damage index; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.
Table 3 Laboratory features of JSLE subgroups at diagnosis
Key laboratory findings
Pre-pubertal
disease-onset (n¼ 43)
Peri-pubertal
disease-onset (n¼ 240) Adolescence (n¼ 135) p value
Haemoglobin level (g/dL) 11 [9–11.9] 11.3 [9.9–12.6] 11.08 [9.7–12.53] 0.404
White cell count
(109/L)
6.7 [4.69–9.53] 6.09 [4.16–8.67] 4.69 [3.7–6.54] 0.002
Platelets (109/L) 293 [212–426] 271 [191–338] 242 [168–298] 0.004
ESR (mm/hr) 18 [11–72] 36 [12–76] 42.5 [19–86.75] 0.200
C3 median (g/L) 0.95 [0.73–1.11] 0.81 [0.50–1.22] 0.69 [0.28–0.98] 0.002
C4 median (g/L) 0.13 [0.08–0.28] 0.11 [0.06–0.19] 0.08 [0.04–0.14] 0.002
ANA positive 37 (86.0%)
[80.7%, 91.3%]
223 (92.9%)
[89.7%, 96.2%]
131 (97.0%)
[94.1%, 99.9%]
0.034
ANA titre median 1:640
[1:320–1:960]
1:640
[1:320–1:1280]
1:640
[1:320–1:2560]
0.565
dsDNA levels (IU/L) 15 [0.25–89] 67 [19–200] 111 [15–300] 0.001
Haemoglobin, white cell count, platelets, ESR, C3, C4, ANA titre and dsDNA titre are reported as median values and interquartile ranges
[in square brackets].
ANA, antinuclear antibodies; CSR, central serous retinopathy; JLSE, juvenile onset systemic lupus erythematous.
Clinical and laboratory characteristics in JSLE
JS Massias et al.
478
Lupus
Discussion
While clinical and laboratory differences between
JSLE and adult-onset SLE have been acknowl-
edged,8 only few and short reports discuss differ-
ences within the paediatric age group.12,13 The 418
JSLE patients included in this study allow for more
reliable assessment of clinical and laboratory fea-
tures between the paediatric age groups. When
compared with younger children, adolescents exhi-
bit an increased number of ACR criteria, and show
typical autoantibody patterns (ANA and anti-
dsDNA positivity), haematological involvement
(leukopenia, thrombocytopenia) and immuno-
logical characteristics (hypocomplementaemia)
reflecting ‘‘classical’’ SLE. Of note, adolescents
also present with higher disease activity at diagno-
sis when compared with younger children (total
numerical BILAG score, p¼ 0.015; and SLEDAI-
2K scores, p¼ 0.001). At diagnosis, differences
were also seen in the organ domains involved
across age groups, including increased mucocuta-
neous, musculoskeletal, cardiorespiratory and
renal system involvement in adolescents when com-
pared with other age groups. Notably, previous
studies did not consider pre-pubertal (7) JSLE
patients as a distinct age group.3,6–8
One of the most interesting differences between
JSLE patients within the three age groups relates to
laboratory findings. Patients diagnosed in early
childhood (7 years) had lower rates of ANA posi-
tivity, with 14% of the pre-pubertal JSLE patients
being ANA negative vs. 3% of the adolescent JSLE
group (p¼ 0.034). Pre-pubertal children also dis-
played lower median anti-dsDNA titres than the
other age groups (p¼ 0.001). These laboratory dif-
ferences may reflect differences in pathophysiology
at varying ages, and a potentially more ‘‘innate’’
disease phenotype in at least a subset of early-
onset JSLE patients.1
Of note, previous studies failed to identify sero-
logical differences between paediatric and adult
SLE populations, which may be due to them not
discriminating between age groups within the JSLE
population3, 8, 22. This potential explanation is sup-
ported by the observation that differences in
immunological patterns (ANA positivity) dis-
appeared by the time of last follow up prior to
transition into adult care (p¼ 0.559). Most patients
who were initially autoantibody negative in the pre-
pubertal (11.7%) and peri-pubertal age groups
(2.9%), eventually developed ANA positivity (pre-
pubertal group: 14% at diagnosis vs. 2% at last
follow up) between the time of initial diagnosis
and last follow-up. It has previously been discussed
that early-onset JSLE patients, who may have a
higher genetic risk when compared with older
SLE patients or have a more monogenic disease
phenotype, can develop autoantibodies over time
as a result of tissue damage, and subsequent pres-
entation of physiologically nuclear components to
the immune system.1,23
This study also found increased frequencies of
ANA positivity to coincide with an increased
prevalence of likely autoantibody-mediated
symptoms, e.g. renal, musculoskeletal and haem-
atological anomalies (thrombocytopenia, lympho-
penia and low complement levels, all p< 0.05).
Autoantibodies (particularly anti-dsDNA antibo-
dies) indeed contribute to renal disease and
immune complex deposition, which may also par-
tially cause the pathologically reduced complement
levels observed with increasing age.2,21,24 Also,
increased musculoskeletal involvement in adult-
onset SLE vs. JSLE patients has been previously
demonstrated.3,8,13 Tavangar-Rad et al. studied
120 Iranian children with JSLE, and compared
age groups in a similar way to the current study
(<7, 7–14, and >14 years) and reported more
joint involvement with increasing age.13 While it
remains unclear why this is, musculoskeletal
involvement is another example of a clinical feature
that may be auto-antibody driven, thus becoming
more prevalent with advancing age at presentation.
Findings from this study also suggest that dis-
ease activity within the paediatric age group may
(at diagnosis) be more severe in individuals diag-
nosed in adolescence, while disease severity
increases over time in children diagnosed at a
younger age. This is indicated by comparable dis-
ease activity and damage scores at last follow up.
Based on variable clinical patterns over time that
coincide with increased disease activity, autoanti-
bodies, immune complex deposition, and comple-
ment activation may likely be involved in this
process.2,21,24 Differences between the present
study and previous reports suggesting increased
disease severity in very early-onset SLE when com-
pared with ‘‘older’’ children with JSLE, may be due
to the character of previous reports.12 Small case
series and individual case reports tend to over-
report particularly severe, interesting and/or com-
plicated presentations and disease courses.
The absence of ANA antibodies in 14% of pre-
pubertal JSLE patients is interesting when con-
sidering the classification criteria for SLE.
Recently proposed ‘‘new’’ ACR/EULAR criteria
for SLE include ANA titres of 1:80 as entry cri-
terion25. While application of these criteria would
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affect only a relatively small number of peri-pub-
ertal or adolescent JSLE patients, 14% of patients
with early disease-onset could potentially remain
without a diagnosis, as classification criteria are fre-
quently (incorrectly) used by colleagues (not neces-
sarily specialized in paediatric rheumatology) to
diagnose SLE and refer to tertiary care. One may
argue that very early disease-onset in the absence of
autoantibodies can indicate genetic conditions
(‘‘monogenic SLE-like disease’’, such as comple-
ment deficiencies, primary type I interferonopa-
thies) and that it is beneficial for patients to not
be classified as ‘‘classical’’ SLE. However, this
may result in diagnostic delays and young patients
not being seen by paediatric rheumatologists.26
Although this study involves one of the largest
national JSLE cohorts available, it is still limited by
JSLE being a rare disease with low patient num-
bers. A power analysis performed prior to this
study suggested that around 700 patients were
required per group for the analysis to be statistic-
ally reliable. Since the UK JSLE cohort study is the
largest JSLE cohort across Europe and one of the
largest in the world, this limitation can unfortu-
nately currently not be addressed. International
collaboration is therefore warranted in the future.
The variable duration of follow up from initial
evaluation to last visit between the three age
groups may also be seen as a potential limitation.
This was caused mainly by the time of transition to
adult care.
Conclusion
This is the largest study to date comparing clinical
and laboratory features of JSLE patients diagnosed
during the pre- (7), peri-pubertal (8–13) and ado-
lescent (14–18) periods. Distinct clinical and
laboratory differences between age groups support
the hypothesis that variable pathomechanisms may
contribute to differences in clinical presentations,
treatment responses and disease outcomes, not
only between adult and paediatric patients but
also within the cohort of JSLE patients. Based on
the presence of autoantibodies and higher preva-
lence of antibody-mediated features (including
thrombocytopenia, lymphopenia, hypocomplemen-
taemia), adaptive immune mechanisms may play an
increasing role with growing age. Disease activity at
diagnosis is higher in individuals diagnosed in ado-
lescence when compared with younger patients.
However, disease severity increases over time in
children diagnosed at a younger age underscoring
the importance of tightly monitored and suffi-
cient treatment in a specialised centre. Though
the largest study of its kind, it is still limited by
patient numbers, due to the rarity of JSLE. Thus,
international collaborations are warranted to
address age-specific differences in JSLE in more
detail.
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